A recent study has shown that Transcranial Magnetic Stimulation (TMS) can reduce symptoms of multiple sclerosis (MS). The procedure was found to significantly reduce symptoms of fatigue in MS patients.
Multiple sclerosis is a disease in which the insulating covers of nerve cells in the spinal cord and brain are damaged. This impacts the nervous systems ability to communicate and results in a range of symptoms. Common symptoms include double vision, blindness, trouble with sensations, issues with coordination, and muscle weakness. Physical fatigue is by far the most common symptoms of MS.
Over 90% of people living with MS suffer from severe fatigue, which can have a serious impact on their personal lives. Many patients with MS are forced to quit work due to this symptom. Fatigue is typically reported as the most bothersome symptom of the disease.
There are very little treatment options currently available for MS. There are limited medications available, and the ones used to treat MS are modestly effective but can have serious side effects and many people cannot tolerate them. The lack of treatment options leads people to seek out alternative solutions despite there being little evidence that they work. But this recent study has highlighted that TMS therapy may be the treatment people have been looking for.
TMS therapy for depression has been FDA approved, specifically treatment-resistant depression. The procedure has been proven to be helpful with other mental disorders though such as PTSD and more studies are undergoing about what mental disorders could benefit from TMS.
dTMS uses a slightly different technique than regular TMS to stimulate deeper into the brain. This deep stimulation has shown to significantly improve fatigue. None of the patients in the study have any serious side effects, proving the treatment is safe for people with MS. The results of the study are promising, and the procedure was successful in relieving the fatigue, which is hard to treat. Hopefully, more studies are done and TMS becomes an FDA approved treatment for MS patients.
The study was conducted by researchers from Charité’s NeuroCure Cluster of Excellence. The study was published in the recent issue of the journal Neurology: Neuroimmunology & Neuroinflammation.
To learn more about TMS and whether or not it’s the right treatment for you, please contact us. We look forward to hearing from you!